News & Updates

Show Multimedia Only

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption

07 Jul 2025 by

LUT014 gel, a novel, small-molecule, topical formulation of a BRAF inhibitor, relieves acneiform rash toxicities from anti-EGFR therapies, findings from a phase II study suggest.

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption

07 Jul 2025

Hormone therapy's impact on young-onset breast cancer risk varies by type

06 Jul 2025

New research shows that using oestrogen hormone therapy alone may reduce the risk of young-onset breast cancer, while combining it with progestin could result in a risk increase among women with intact uterus and ovaries.

Hormone therapy's impact on young-onset breast cancer risk varies by type

06 Jul 2025

CDK4/6 inhibitor-induced liver injury common in breast cancer

05 Jul 2025 by

Liver injury occurs in around one in 20 patients treated with cyclin-dependent kinase 4/6 inhibitors for metastatic breast cancer, according to a multicentre retrospective study in Spain.

CDK4/6 inhibitor-induced liver injury common in breast cancer

05 Jul 2025

DESTINY-Breast09: T-DXd plus pertuzumab improves PFS in HER2+ breast cancer

05 Jul 2025 by

Treatment with trastuzumab deruxtecan (T-DXd) plus pertuzumab significantly improved progression-free survival (PFS) in patients with HER2+ advanced/metastatic breast cancer (a/mBC) compared with standard of care in the first-line setting, according to a planned interim analysis of the phase III DESTINY-Breast09 trial presented at ASCO 2025.

DESTINY-Breast09: T-DXd plus pertuzumab improves PFS in HER2+ breast cancer

05 Jul 2025

TTFields a new treatment paradigm for unresectable pancreatic cancer?

04 Jul 2025 by

Tumour treating fields (TTFields) added to first-line chemotherapy (gemcitabine and nab-paclitaxel [GnP]) extends survival in individuals with locally advanced pancreatic adenocarcinoma (LA-PAC) in the PANOVA-3 study.

TTFields a new treatment paradigm for unresectable pancreatic cancer?

04 Jul 2025

First-line benmelstobart–anlotinib combo yields PFS gain in advanced PD-L1-positive NSCLC

03 Jul 2025 by

In the first-line treatment of patients with advanced PD-L1–positive non–small cell lung cancer (NSCLC), the combination of the anti-PD-L1 monoclonal antibody benmelstobart plus the multikinase inhibitor anlotinib prolongs progression-free survival (PFS) compared with pembrolizumab monotherapy, according to the phase III CAMPASS study conducted in China.

First-line benmelstobart–anlotinib combo yields PFS gain in advanced PD-L1-positive NSCLC

03 Jul 2025

Ropeginterferon α-2b extends benefit to another rare blood cancer

03 Jul 2025 by

Topline results of the phase III SURPASS-ET trial show the superior efficacy of ropeginterferon α-2b (ropeg) compared with anagrelide as second-line (2L) treatment for high-risk essential thrombocythaemia (ET), a rare blood cancer that may progress to myelofibrosis or acute myeloid leukaemia.

Ropeginterferon α-2b extends benefit to another rare blood cancer

03 Jul 2025

Utidelone plus bevacizumab shows promise in ERBB2-negative MBC

03 Jul 2025

Combination treatment with utidelone plus bevacizumab has demonstrated therapeutic potential in patients with ERBB2-negative metastatic breast cancer (MBC) and active brain metastases in a single-arm, phase II study conducted in China.